IL2 and melanoma: To assess the feasibility of BE for TIL engineering, we implemented ABE to target co-inhibitory receptors in TILs from ovarian (Ova-TIL) or melanoma (Mel-TIL) patients expanded with high dose IL-2 by conventional REP (schematic in Figure 1A).